QDEL Heads Into Earnings With Shorts Covering and Options Calmer

QuidelOrtho reports Q3 results today carrying one of the more striking turnarounds in its own positioning: a stock that collapsed 64% in the year to September has gained 31% in a single month, and the bears who built that position are now covering.

The clearest signal is in short interest, which fell 13% in one week to 19.1% of the free float. That is still a heavy position in absolute terms, over 12.9 million shares, with days-to-cover running close to five. But the direction has shifted decisively. Shorts who built up to roughly 15 million shares in mid-October began unwinding sharply in the last week of October, suggesting at least some bears have decided the risk of holding through the print is too high. The lending market tells a consistent story: availability is at 460%, well above the 52-week floor of 212%, meaning there is no structural tightness trapping anyone in a borrow. Cost to borrow at 0.63% is low, though it has crept up 23% over the past week. The ORTEX short score, at 65.2 and drifting down from above 68 two weeks ago, confirms the same softening in bearish conviction.

Options, by contrast, are unusually quiet. The put/call ratio of 1.00 is fractionally below its 20-day average of 1.03 and well beneath the more defensive readings that characterised September, when the PCR ran above 1.19. That is a notable change: six weeks ago, options traders were paying up for downside protection; now, with the stock up sharply, the market is not rushing to repeat the trade. The 52-week range on the PCR runs from 0.21 to 2.41, so a reading of 1.00 is genuinely neutral.

The bull-bear debate is sharpening into a question about execution. Bulls point to free cash flow generation, the breadth added by the Ortho merger, and the long-term cost savings expected from the ERP consolidation. Bears focus on three unresolved risks: Savanna product launch uncertainty, margin pressure, and a debt load that limits manoeuvring room. Analyst consensus has not moved since August, and the most recent price-target data predates the August print, when the stock fell 30% in a single session after what was evidently a poor quarter. Targets from Citigroup, JPMorgan and others reflect that reality: they were already cut sharply in May and July and sit in the $12 to $18 range. The mean target of around $14.70 is close to where the stock is trading today, leaving minimal implied upside in the consensus even after the recent rally. The 30-point collapse in the Jefferies target from $35 to $12.50, alongside a downgrade to Hold in May, captures how dramatically the narrative shifted earlier this year.

One institutional move is worth flagging. Newtyn Management raised its stake to 9.7% in its most recent 13G filing in August, up from 7.8% previously. BlackRock added over 750,000 shares in Q3 and holds 16.3% of shares. FMR, however, has cut sharply, filing a reduced position of 5.8% against 11.5% previously. These are passive disclosures, and stakes are as-last-disclosed around the 5% threshold. Still, the Newtyn build alongside Fidelity's exit gives the ownership picture a contested look.

The print is therefore less about whether QuidelOrtho is recovering and more about whether management can demonstrate the Savanna rollout and ERP transition are under control, with enough margin stabilisation to justify the 31% re-rating the market handed the stock in October.